The microbiome is receiving significant attention given its influence on a host of human
diseases including cancer. Its role in response to cancer treatment is becoming increasingly …

Immunotherapy is currently the most rapidly advancing area of clinical oncology, and
provides the unprecedented opportunity to effectively treat, and even cure, several …

PD-1 blockade is a cancer immunotherapy effective in various types of cancer. In a fraction
of treated patients, however, it causes rapid cancer progression called hyperprogressive …

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of
immune-based therapies, including the widely used class of agents known as immune …

Background Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting
cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its …

The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an
exciting era of anticancer therapy. Durable responses can be seen in patients with …

Accumulating evidence suggests that exogenous cellular stress induces PD-L1 upregulation
in cancer. A DNA double-strand break (DSB) is the most critical type of genotoxic stress, but …

Purpose We conducted a retrospective analysis to assess the safety profile of nivolumab
monotherapy in patients with advanced melanoma and describe the management of …

Gloss PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has
elicited durable antitumor responses and long-term remissions in a subset of patients with a …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …